Caspofungin salvage therapy in a neutropenic patient with probable invasive aspergillosis: A case report

Supportive Care in Cancer

Volumn 11, Issue 11, 2003, Pages 742-744

  Taccone, F S ^a   Marechal, R ^a   Meuleman, N ^a   Aoun, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Caspofungin; Invasive pulmonary aspergillosis; Neutropenia

Indexed keywords

AMIKACIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ITRACONAZOLE; MEROPENEM; METHOTREXATE; MITOXANTRONE; TEICOPLANIN; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ANAMNESIS; ARTICLE; ASPERGILLUS FUMIGATUS; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CELLULITIS; CLINICAL FEATURE; DIABETES INSIPIDUS; DIAGNOSTIC PROCEDURE; DISEASE ACTIVITY; DISEASE COURSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HOSPITAL ADMISSION; HUMAN; HYPOKALEMIA; INTENSIVE CARE UNIT; KIDNEY TUBULE DISORDER; LABORATORY TEST; LIVER DISEASE; LUNG ASPERGILLOSIS; MALE; NEPHROTOXICITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RESPIRATORY FAILURE; SALVAGE THERAPY; STAPHYLOCOCCUS AUREUS;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ASPERGILLOSIS; HUMANS; LEUKEMIA, B-CELL, ACUTE; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; NEUTROPENIA; PEPTIDES; PEPTIDES, CYCLIC; REMISSION INDUCTION; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 0242413718     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-003-0522-0     Document Type: Article

References (7)

1. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34(1):7-14
2. Graybill JR (2001) The echinocandins, first novel class of antifungal in two decades: will they live up to their promise?. Int J Clin Pract 55(9):633-638
3. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6):408-415
4. Keating GM and Jarvis B (2001) Caspofungin. Drugs 61(8):1121-1129
5. Maertens J, Raad I, Sable CA, Ngai A, Berman R, Patterson TF, Denning D and Walsh T (2000) Multicenter non-comparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory or intolerant to amphotericin B, amphotericin lipid formulations or azoles. Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2002, USA
6. Parquin F (2000). Prevention du risque aspergillaire chez les patients immunodeprimés". Conference de consensus, Institut Pasteur-Paris, 21/03/2000
7. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ and Pfaller MA (2002) Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 43:13-17